Company profile
CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VOLAMCABTAGENE DURZIGEDLEUCEL | phase1 | — | 2 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04035434 | phase1_2 | terminated | 2019-07-22 | 2024-10-04 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) |
| NCT06925542 | phase1 | recruiting | 2025-03-10 | 2031-12-31 | CRISPR Therapeutics | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease |
| NCT07804004 | phase1_2 | not_yet_recruiting | 2026-09-15 | 2029-12-30 | CRISPR Therapeutics | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease |
| NCT05643742 | phase1_2 | recruiting | 2023-03-10 | 2030-01-01 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies |
| NCT04244656 | phase1 | terminated | 2020-01-22 | 2024-01-04 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma |
FDA applications (0)
No records yet.